Tumours of Haematopoietic and Lymphoid Tissues: Difference between revisions
| [unchecked revision] | [unchecked revision] |
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
== Myeloproliferative Neoplasms (MPN) == | ==Myeloproliferative Neoplasms (MPN)== | ||
*[[Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive]] | *[[Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive]] | ||
*[[Chronic Neutrophilic Leukemia (CNL)]] | *[[Chronic Neutrophilic Leukemia (CNL)]] | ||
| Line 8: | Line 9: | ||
*[[Myeloproliferative Neoplasm (MPN), Unclassifiable]] | *[[Myeloproliferative Neoplasm (MPN), Unclassifiable]] | ||
== Mastocytosis == | ==Mastocytosis== | ||
*[[Cutaneous Mastocytosis]] | *[[Cutaneous Mastocytosis]] | ||
*[[Systemic Mastocytosis]] | *[[Systemic Mastocytosis]] | ||
*[[Mast Cell Sarcoma]] | *[[Mast Cell Sarcoma]] | ||
== Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of PDGFRA, PDGFRB or FGFR1, or with PCM1-JAK2 == | ==Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of PDGFRA, PDGFRB or FGFR1, or with PCM1-JAK2== | ||
*[[Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement]] | *[[Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement]] | ||
*[[Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement]] | *[[Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement]] | ||
| Line 19: | Line 22: | ||
*[[Myeloid/Lymphoid Neoplasms with PCM1-JAK2]] | *[[Myeloid/Lymphoid Neoplasms with PCM1-JAK2]] | ||
== Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) == | ==Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)== | ||
*[[Chronic Myelomonocytic Leukemia (CMML)]] | *[[Chronic Myelomonocytic Leukemia (CMML)]] | ||
*[[Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative]] | *[[Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative]] | ||
| Line 26: | Line 30: | ||
*[[Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable|MDS/MPN, Unclassifiable]] | *[[Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable|MDS/MPN, Unclassifiable]] | ||
== Myelodysplastic Syndromes (MDS) == | ==Myelodysplastic Syndromes (MDS)== | ||
*[[Myelodysplastic Syndrome (MDS) with Single Lineage Dysplasia|MDS with Single Lineage Dysplasia]] | *[[Myelodysplastic Syndrome (MDS) with Single Lineage Dysplasia|MDS with Single Lineage Dysplasia]] | ||
*[[Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS)|MDS with Ring Sideroblasts (MDS-RS)]] | *[[Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS)|MDS with Ring Sideroblasts (MDS-RS)]] | ||
| Line 36: | Line 41: | ||
*[[Refractory Cytopenia of Childhood]] | *[[Refractory Cytopenia of Childhood]] | ||
== Myeloid Neoplasms with Germline Predisposition == | ==Myeloid Neoplasms with Germline Predisposition== | ||
*[[Acute Myeloid Leukaemia with Germline CEBPA Mutation]] | *[[Acute Myeloid Leukaemia with Germline CEBPA Mutation]] | ||
| Line 45: | Line 50: | ||
*[[Myeloid Neoplasms with Germline GATA2 Mutation]] | *[[Myeloid Neoplasms with Germline GATA2 Mutation]] | ||
== Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms == | ==Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms== | ||
*[[Acute Myeloid Leukemia (AML) with Recurrent Genetic Abnormalities|AML with Recurrent Genetic Abnormalities]] | *[[Acute Myeloid Leukemia (AML) with Recurrent Genetic Abnormalities|AML with Recurrent Genetic Abnormalities]] | ||
| Line 83: | Line 89: | ||
- [[Myeloid Leukemia Associated with Down Syndrome]] | - [[Myeloid Leukemia Associated with Down Syndrome]] | ||
== Blastic Plasmacytoid Dendritic Cell Neoplasm == | ==Blastic Plasmacytoid Dendritic Cell Neoplasm== | ||
*[[Blastic Plasmacytoid Dendritic Cell Neoplasm]] | *[[Blastic Plasmacytoid Dendritic Cell Neoplasm]] | ||
== Acute Leukemias of Ambiguous Lineage (MPAL) == | ==Acute Leukemias of Ambiguous Lineage (MPAL)== | ||
*[[Acute Leukemias of Ambiguous Lineage]] | *[[Acute Leukemias of Ambiguous Lineage]] | ||
| Line 97: | Line 105: | ||
- [[Acute Leukemias of Ambiguous Lineage, Not Otherwise Specified (NOS)]] | - [[Acute Leukemias of Ambiguous Lineage, Not Otherwise Specified (NOS)]] | ||
== Precursor Lymphoid Neoplasms (B-ALL, T-ALL) == | ==Precursor Lymphoid Neoplasms (B-ALL, T-ALL)== | ||
*[[B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic Abnormalities|B-Lymphoblastic Leukemia/Lymphoma (B-ALL) with Recurrent Genetic Abnormalities]] | *[[B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic Abnormalities|B-Lymphoblastic Leukemia/Lymphoma (B-ALL) with Recurrent Genetic Abnormalities]] | ||
| Line 116: | Line 125: | ||
- [[NK-Lymphoblastic Leukemia/Lymphoma]] | - [[NK-Lymphoblastic Leukemia/Lymphoma]] | ||
== Mature B-Cell Neoplasms (CLL, Plasma Cell Neoplasms, Non-Hodgkin B-cell Lymphomas) == | ==Mature B-Cell Neoplasms (CLL, Plasma Cell Neoplasms, Non-Hodgkin B-cell Lymphomas)== | ||
*[[Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma]] | *[[Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma]] | ||
- [[Monoclonal B-cell Lymphocytosis]] | - [[Monoclonal B-cell Lymphocytosis]] | ||
| Line 127: | Line 138: | ||
*[[Splenic B-cell Lymphoma/Leukemia, Unclassifiable]] | *[[Splenic B-cell Lymphoma/Leukemia, Unclassifiable]] | ||
- [[Splenic Diffuse Red Pulp Small B-cell Lymphoma]] | - [[Splenic Diffuse Red Pulp Small B-cell Lymphoma]] | ||
- [[Hairy Cell Leukemia Variant]] | - [[Hairy Cell Leukemia Variant]] | ||
*[[Lymphoplasmacytic Lymphoma]] | *[[Lymphoplasmacytic Lymphoma]] | ||
- [[Waldenstrom Macroglobulinemia]] | - [[Waldenstrom Macroglobulinemia]] | ||
| Line 136: | Line 149: | ||
*[[Heavy Chain Diseases]] | *[[Heavy Chain Diseases]] | ||
- [[Mu Heavy Chain Disease]] | - [[Mu Heavy Chain Disease]] | ||
- [[Gamma Heavy Chain Disease]] | - [[Gamma Heavy Chain Disease]] | ||
| Line 141: | Line 155: | ||
*[[Plasma Cell Neoplasms]] | *[[Plasma Cell Neoplasms]] | ||
- [[Non-IgM Monoclonal Gammopathy of Undetermined Significance]] | - [[Non-IgM Monoclonal Gammopathy of Undetermined Significance]] | ||
- [[Plasma Cell Myeloma]] | - [[Plasma Cell Myeloma]] | ||
| Line 155: | Line 170: | ||
*[[Nodal Marginal Zone Lymphoma]] | *[[Nodal Marginal Zone Lymphoma]] | ||
- [[Paediatric Nodal Marginal Zone Lymphoma]] | - [[Paediatric Nodal Marginal Zone Lymphoma]] | ||
*[[Follicular Lymphoma]] | *[[Follicular Lymphoma]] | ||
- [[Testicular Follicular Lymphoma]] | - [[Testicular Follicular Lymphoma]] | ||
- [[In Situ Follicular Neoplasia]] | - [[In Situ Follicular Neoplasia]] | ||
| Line 169: | Line 186: | ||
*[[Mantle Cell Lymphoma]] | *[[Mantle Cell Lymphoma]] | ||
- [[Leukemic Non-Nodal Mantle Cell Lymphoma]] | - [[Leukemic Non-Nodal Mantle Cell Lymphoma]] | ||
- [[In Situ Mantle Cell Neoplasia]] | - [[In Situ Mantle Cell Neoplasia]] | ||
| Line 185: | Line 203: | ||
*[[Diffuse Large B-cell Lymphoma Associated with Chronic Inflammation]] | *[[Diffuse Large B-cell Lymphoma Associated with Chronic Inflammation]] | ||
- [[Fibrin-Associated Diffuse Large B-cell Lymphoma]] | - [[Fibrin-Associated Diffuse Large B-cell Lymphoma]] | ||
| Line 200: | Line 219: | ||
*[[HHV8-Associated Lymphoproliferative Disorders]] | *[[HHV8-Associated Lymphoproliferative Disorders]] | ||
- [[Multicentric Castleman Disease]] | - [[Multicentric Castleman Disease]] | ||
- [[HHV8-Positive Diffuse Large B-cell Lymphoma, Not Otherwise Specified (NOS)]] | - [[HHV8-Positive Diffuse Large B-cell Lymphoma, Not Otherwise Specified (NOS)]] | ||
| Line 209: | Line 229: | ||
*[[High-Grade B-cell Lymphoma]] | *[[High-Grade B-cell Lymphoma]] | ||
- [[High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements]] | - [[High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements]] | ||
- [[High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS)]] | - [[High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS)]] | ||
| Line 214: | Line 235: | ||
*[[B-cell Lymphoma, Unclassifiable, with Features Intermediate Between Diffuse Large B-cell Lymphoma and Classic Hodgkin Lymphoma]] | *[[B-cell Lymphoma, Unclassifiable, with Features Intermediate Between Diffuse Large B-cell Lymphoma and Classic Hodgkin Lymphoma]] | ||
== Mature T- and NK-cell Neoplasms == | ==Mature T- and NK-cell Neoplasms== | ||
*[[T-cell Prolymphocytic Leukemia]] | *[[T-cell Prolymphocytic Leukemia]] | ||
| Line 224: | Line 246: | ||
*[[EBV-Positive T-cell and NK-cell Lymphoproliferative Diseases of Childhood]] | *[[EBV-Positive T-cell and NK-cell Lymphoproliferative Diseases of Childhood]] | ||
- [[Systemic EBV-Positive T-cell Lymphoma of Childhood]] | - [[Systemic EBV-Positive T-cell Lymphoma of Childhood]] | ||
- [[Chronic Active EBV Infection of T- and NK-cell Type, Systemic Form]] | - [[Chronic Active EBV Infection of T- and NK-cell Type, Systemic Form]] | ||
| Line 234: | Line 257: | ||
*[[Intestinal T-cell Lymphoma]] | *[[Intestinal T-cell Lymphoma]] | ||
- [[Enteropathy-Associated T-cell Lymphoma]] | - [[Enteropathy-Associated T-cell Lymphoma]] | ||
- [[Monomorphic Epitheliotropic Intestinal T-cell Lymphoma]] | - [[Monomorphic Epitheliotropic Intestinal T-cell Lymphoma]] | ||
| Line 248: | Line 272: | ||
*[[Primary Cutaneous CD30 Positive T-cell Lymphoproliferative Disorders]] | *[[Primary Cutaneous CD30 Positive T-cell Lymphoproliferative Disorders]] | ||
- [[Lymphomatoid Papulosis]] | - [[Lymphomatoid Papulosis]] | ||
- [[Primary Cutaneous Anaplastic Large Cell Lymphoma]] | - [[Primary Cutaneous Anaplastic Large Cell Lymphoma]] | ||
*[[Primary Cutaneous Peripheral T-cell Lymphomas, Rare Subtypes]] | *[[Primary Cutaneous Peripheral T-cell Lymphomas, Rare Subtypes]] | ||
- [[Primary Cutaneous Gamma Delta T-cell Lymphoma]] | - [[Primary Cutaneous Gamma Delta T-cell Lymphoma]] | ||
- [[Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-cell Lymphoma]] | - [[Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-cell Lymphoma]] | ||
| Line 260: | Line 286: | ||
*[[Angioimmunoblastic T-cell Lymphoma and Other Nodal Lymphomas of T Follicular Helper Cell Origin]] | *[[Angioimmunoblastic T-cell Lymphoma and Other Nodal Lymphomas of T Follicular Helper Cell Origin]] | ||
- [[Angioimmunoblastic T-cell Lymphoma]] | - [[Angioimmunoblastic T-cell Lymphoma]] | ||
- [[Follicular T-cell Lymphoma]] | - [[Follicular T-cell Lymphoma]] | ||
| Line 270: | Line 297: | ||
*[[Breast Implant-Associated Anaplastic Large Cell Lymphoma]] | *[[Breast Implant-Associated Anaplastic Large Cell Lymphoma]] | ||
== Hodgkin Lymphomas== | ==Hodgkin Lymphomas== | ||
*[[Nodular Lymphocyte Predominant Hodgkin Lymphoma]] | *[[Nodular Lymphocyte Predominant Hodgkin Lymphoma]] | ||
*[[Classic Hodgkin Lymphoma]] | *[[Classic Hodgkin Lymphoma]] | ||
- [[Nodular Sclerosis Classic Hodgkin Lymphoma]] | - [[Nodular Sclerosis Classic Hodgkin Lymphoma]] | ||
- [[Lymphocyte-Rich Classic Hodgkin Lymphoma]] | - [[Lymphocyte-Rich Classic Hodgkin Lymphoma]] | ||
| Line 279: | Line 308: | ||
- [[Lymphocyte-Depleted Classic Hodgkin Lymphoma]] | - [[Lymphocyte-Depleted Classic Hodgkin Lymphoma]] | ||
== Immunodeficiency-Associated Lymphoproliferative Disorders== | ==Immunodeficiency-Associated Lymphoproliferative Disorders== | ||
*[[Lymphomas Associated with HIV Infection]] | *[[Lymphomas Associated with HIV Infection]] | ||
*[[Post-Transplant Lymphoproliferative Disorders]] | *[[Post-Transplant Lymphoproliferative Disorders]] | ||
- [[Non-Destructive Post-Transplant Lymphoproliferative Disorders]] | - [[Non-Destructive Post-Transplant Lymphoproliferative Disorders]] | ||
- [[Polymorphic Post-Transplant Lymphoproliferative Disorders]] | - [[Polymorphic Post-Transplant Lymphoproliferative Disorders]] | ||
| Line 292: | Line 323: | ||
*[[Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders]] | *[[Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders]] | ||
== Histiocytic and Dendritic Cell Neoplasms == | ==Histiocytic and Dendritic Cell Neoplasms== | ||
*[[Histiocytic Sarcoma]] | *[[Histiocytic Sarcoma]] | ||
*[[Tumors Derived From Langerhans Cells]] | *[[Tumors Derived From Langerhans Cells]] | ||
- [[Langerhans Cell Histiocytosis]] | - [[Langerhans Cell Histiocytosis]] | ||
- [[Langerhans Cell Sarcoma]] | - [[Langerhans Cell Sarcoma]] | ||
| Line 304: | Line 337: | ||
*[[Follicular Dendritic Cell Sarcoma]] | *[[Follicular Dendritic Cell Sarcoma]] | ||
- [[Inflammatory Pseudotumor-Like Follicular/Fibroblastic Dendritic Cell Sarcoma]] | - [[Inflammatory Pseudotumor-Like Follicular/Fibroblastic Dendritic Cell Sarcoma]] | ||
| Line 313: | Line 347: | ||
NOTES | NOTES | ||
The hierarchical tumour classification structure displayed on this page is reproduced from the WHO Classification of Tumours with permission from the copyright holder, ©International Agency for Research on Cancer. | The hierarchical tumour classification structure displayed on this page is reproduced from the [https://tumourclassification.iarc.who.int/welcome/ WHO Classification of Tumours] with permission from the copyright holder, ©International Agency for Research on Cancer. | ||